Obondo James Sande

Lecturer

Makerere University College of Health Sciences, Uganda

Tel: +256 772747940

Email: ojsande@gmail.com

VALIDATE Role:

Network Associate

Research Keywords:

TB, Leishmaniasis, clinical trials

Biography:

Myresearch is focused on two areas: 1) T cell response to M. tuberculosis and Leishmania donovani, and the immune system pathways these pathogens takes advantage of to evade host immunity, and 2) Drug development and immunotherapy for infectious diseases. I am currently a member of the research team on a clinical trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stigbogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Uganda

Related Websites:

Department of Immunology & Molecular Biology

Key Publications:

Obondo J. Sande, Ahmad F. Karim, Qing Li,Xuedong Ding, Clifford V. Harding, Roxana E. Rojas, and W. Henry Boom. Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4+ T cell Anergy via GRAIL. J Immunol. 2016 Jan 15; 196 (2): 691-702. doi: 10.4049/jimmunol.1500710. PubMed PMID: 26667170.

Ahmad F. Karim, Obondo J. Sande, Sara E.Tomeckho, Xuedong Ding, Rob M. Ewing, Clifford V. Harding, Mark R. Chance, Roxana E. Rojas and W. Henry Boom.Proteomics analysis reveals inhibition of Akt-mTOR signaling in CD4+ T cells by Mycobacterium tuberculosis Mannose-capped Lipoarabinomannan. Protoemics, 10. 2017.

Robert N. Mahon*, Obondo J. Sande*, Roxana E. Rojas, Alan D. Levine, Clifford V. Harding and W. Henry Boom. Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with Zap70, Lck and LAT phosphorylation. Cell Immunol. 2012 Jan-Feb; 275(1-2):98-105. doi: 10.1016/j.cellimm.2012.02.009. PubMed PMID: 22507872.